An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

BioNTech (BNTX) has drawn fresh attention after recent share price moves, with the stock up around 9% over the past week and ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments ...

Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a glimpse ...

BioNTech SE's stock saw a spike in September due to positive data from Summit Therapeutics' ivonescimab, which has a similar mechanism to BioNTech's BNT327. BioNTech's Q3 earnings showed improved ...

Today, Benzinga's options scanner spotted 20 options trades for BioNTech. This is not a typical pattern. The sentiment among these major traders is split, with 55% bullish and 20% bearish. Among all ...

I rate BioNTech SE a hold due to volatile financial performance, weak growth, and premium valuation. The company's financials are heavily reliant on COVID-19 vaccines, with declining demand impacting ...

An update from BioNTech SE ( ($BNTX) ) is now available. On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously ...

BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...

Following the completion of the share exchange offer in December, BioNTech swiftly moved to acquire the remaining outstanding shares, achieving full integration of CureVac's business operations.